We work as embedded advisors
for Pharma and Biotech companies,
from planning for first approval
to global portfolio management.
The challenges we tackle…
- require a thorough understanding of scientific and medical principles
- inform strategic decision-making and prioritization of activities
- are deeply embedded in our clients' organizational context
The results we produce…
- are as simple as possible while fully considering scientific complexity and clinical nuances
- focus on what is truly essential, enabling excellent execution in a reality of limited resources
- provide the rationale for leadership endorsement and set the team up for successful tactical execution
Experience, education and values – our foundation
Scientific and medical backgrounds
combined with experience in business strategy
Agility and proactivity in collaborating
with clients from large pharma to emerging biotechs
Culture prioritizing quality over quantity,
outcomes over hours worked, people over processes
Areas of Experience
Medical Strategy
Medical Strategy and Plan development, asset- or patient centric
Ongoing strategic support for Medical Affairs incl. temporary Medical Director support
Approval Readiness setup and tracking for Medical Affairs and cross-functionally
Engagement Strategy including external expert mapping, prioritization and channels
Evidence Strategy
Integrated Evidence Generation Plan (IEGP) development for a specific asset or therapeutic area
Evidence Gap Analysis
Evidence Landscape and evolution (incl. e.g., upcoming readouts of clinical trials and other activities)
Communication/ Publication Strategy and plan
Clinical Strategy and New Product Planning
Portfolio Strategy for a specific therapeutic area or technology platform
Clinical Development Plan for a single, a pipeline, or a subset of assets
Competitive Landscape Assessment and Competitor TPPs
We also support early-stage Biotechs,
from pre-clinical to first-in-human studies
Our therapeutic area experience extends across oncology, hematology, rare disease, neurology, cardiovascular, metabolic disorders, and more.
Technologies we're familiar with include (multi-specific) antibodies, allogeneic and autologous cellular therapies, antibody-drug conjugates, peptide-receptor-radionuclide-therapy and -diagnostics, protein degraders, and gene therapies.
The companies we work with range from Biotechs planning for first commercial launch to global Pharma companies. We typically work with Medical Affairs or Commercial leads for an asset, technology, therapeutic area pipeline, or portfolio.
We combine scientific expertise and strategic thinking to arrive at actionable results, setting clients up for execution in their specific business context.